SVP David Ryan sold 5,230 shares of ABBV at $233.56; retained 2,654 shares (-66.3% of holdings).
Purdue David Ryan, as SVP and Controller at AbbVie, executed a substantial sale of 5,230 shares on 2026-03-04 at $233.56 per share, reducing his holdings from 7,884 to 2,654 shares—a reduction of 66.3% of his prior position. The stock is currently trading at $230.11, only 5.8% below its 52-week high of $244.38, and has gained 6.0% over the prior 30 days. The company reported latest-quarter revenue of $15,776,000,000.00 with net income of $186,000,000.00 and achieved 8.6% annual revenue growth. This sale represents a material reduction in his direct equity stake, though the controller retains meaningful holdings, suggesting neither full conviction departure nor complete disengagement from the company's future performance.